An observational study in Pacemaker, Leadless Pacemaker and Cardiac Pacing, Artificial, sponsored by Karl Landsteiner University of Health Sciences. Recruiting at 1 site in Austria. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by Karl Landsteiner University of Health Sciences · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Bradycardia with a site in Austria — 7 open to participants now, 7 under way, none of them phase 3. Bradycardia · Austria.
Among the 26 studies in Bradycardia with a site in Austria, this one is the 7th largest by planned enrollment of the 11 observational ones that give a count, is the only one that started in 2015, is one of 11 observational ones, and was the 24th registered.
317 studies on the registry are indexed under Bradycardia; 71 are open to participants now.
Browse Bradycardia studies →7 of the 26 studies in Bradycardia with a site in Austria are open now. Recruiting first, the newest first:
Biotronik SE & Co. KG · Sites in Austria, Australia, Czechia and 10 more countries
Ages 18+
Biotronik, Inc. · Sites in Austria, United States, Australia and 5 more countries
Ages 18+
MicroPort CRM · Sites in Austria, Belgium, France and 5 more countries
Ages 18+
Medical University Innsbruck · Sites in Austria
Ages 18+
Medtronic · Sites in Austria, United States, Australia and 32 more countries
A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →
Of the 51 Bradycardia studies recruiting now, 34 (67%) set no upper age limit and 9 (18%) stop at 75 or younger; 4 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 1983; this study’s year is marked. 1 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 700 is above the median of 257 across 127 observational studies indexed under Bradycardia.
Median enrollment 129 across the 15 interventional studies, 870 across the 11 observational. Of the 18 that completed or were terminated, 9 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 26 have an industry lead sponsor. The 10 most frequent:
Karl Landsteiner University of Health Sciences is the lead sponsor of 13 studies on the registry; 8 are open to participants now.
Karl Landsteiner University of Health Sciences has 2 studies filed under Bradycardia — fewer than ten, so there is no comparison to draw.
1 of the studies in Bradycardia with a site in Austria that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07118358Biotronik, Inc.BIOTRONIK Investigation of the LivIQ Leadless Pacemaker System | 2027-03 |
Add it to your calendar (.ics) → With an account.
Among the 26 studies in Bradycardia with a site in Austria, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The registry for leadless pacemakers will collect and annually analyze the data of all leadless pacemaker implantations at the University Hospital St. Pölten, including demographic information, indications, procedural details, acute, medium- and long-term complications during follow-up. Due to the partially novel nature of the signals (atrial mechanical sensing markers) and the lack of long-term experience to date, data on these aspects will also be collected and analyzed.
This is a single-center, prospective and retrospective registry that includes all patients receiving a leadless pacing device, as well as all patients who received a leadless pacing device between January 2021 and the start of the registry. All patients undergoing implantation of a leadless pacemaker will be invited to participate in the registry. For patients to be included retrospectively, participation in the registry will be offered at the time of their next routine follow-up visit.
The indication for leadless pacing will be determined by the physician responsible for the patient. Enrollment in the registry will in no case alter or influence the treatment the patient receives. Data collection will take place at the time of implantation and continuously during follow-up over the entire study period. Pacemaker-related data may be obtained either in person or via remote monitoring.
The study population consists of adult patients undergoing implantation of a leadless pacemaker at University Hospital St. Pölten, as well as patients who previously received a leadless pacemaker at the same institution since June 2015. Both prospective and retrospective patients are included.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Procedural success rate
Successful implantation of a leadless pacemaker with acceptable electrical parameters and no need for conversion to a transvenous system
Time frame: Periprocedural / at Day 1
Incidence of acute complications
Rate of periprocedural complications (e.g., vascular complications, arrhythmias, pericardial effusion, device dislodgement)
Time frame: Within 30 days after implantation
Device-related complication rate (medium- and long-term)
Cumulative incidence of complications requiring medical or surgical intervention (e.g., device malfunction, infection, need for extraction, upgrade)
Time frame: Up to 10 years after implantation
Ventricular pacing burden
Percentage of ventricular pacing and triggered pacing as recorded by device interrogation
Time frame: Day 1, 3 months post-implant (±2 weeks), 1 year after Implantation (±2 weeks), every 12th month (±2 weeks) thereafter
All-cause mortality
Time frame: Throughout follow-up (up to 10 years)
Hospitalizations related to cardiac arrhythmias or heart failure
Time frame: Throughout follow-up (up to 10 years)
Quality of Life after Implantation
Change in 12-Item Short Form Health Survey (SF-12) questionnaire score / The SF-12 questionnaire is a validated health-related quality of life instrument with two subscales: Physical Component Summary (PCS) and Mental Component Summary (MCS). Each subscale ranges from 0 to 100 points, where higher scores indicate better health-related quality of life.
Time frame: 1 year after Implantation (±2 weeks), every 12th month (±2 weeks) thereafter
Electrical performance of the device
Pacing thresholds (in Volts at 0.24 ms pulse width)
Time frame: Day 1, 3 months post-implant (±2 weeks), 1 year after Implantation (±2 weeks), every 12th month (±2 weeks) thereafter
Electrical performance of the device
Sensing Amplitude (R-wave, in millivolts \[mV\])
Time frame: Day 1, 3 months post-implant (±2 weeks), 1 year after Implantation (±2 weeks), every 12th month (±2 weeks) thereafter
Electrical performance of the device
Lead impedance (in Ohms \[Ω\])
Time frame: Day 1, 3 months post-implant (±2 weeks), 1 year after Implantation (±2 weeks), every 12th month (±2 weeks) thereafter
Electrical performance of the device
Estimated battery longevity (in years)
Time frame: Day 1, 3 months post-implant (±2 weeks), 1 year after Implantation (±2 weeks), every 12th month (±2 weeks) thereafter
Left ventricular ejection fraction on Echocardiography
in %
Time frame: 1 year after Implantation (±2 weeks), every 12th month (±2 weeks) thereafter
Left ventricular dimensions on Echocardiography
end-diastolic and end-systolic diameters, in mm
Time frame: 1 year after Implantation (±2 weeks), every 12th month (±2 weeks) thereafter
Right ventricular function on Echocardiography
Tricuspid Annular Plane Systolic Excursion (TAPSE) in mm
Time frame: 1 year after Implantation (±2 weeks), every 12th month (±2 weeks) thereafter
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2015 (actual). Primary completion is estimated for Jan 2035, 235 months after the start.
Of 73 observational studies under Bradycardia, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 96. This study's planned 235 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Karl Landsteiner University of Health Sciences